Active Ingredient: Maprotiline

Indication for Maprotiline

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure
  • Depression
  • Endogenous and late-onset (involutional) depression.
  • Psychogenic, reactive, and neurotic depression, exhaustion depression.
  • Somatogenic depression.
  • Masked depression.
  • Menopausal depression.
  • Other depressive mood disorders characterised by anxiety, dysphoria, or irritability; apathetic states (especially in the elderly); psychosomatic and somatic symptoms with underlying depression and/or anxiety.

For this indication, competent medicine agencies globally authorize below treatments:

25-150 mg daily


Dosage regimens

Oral, in total between 25 milligrams maprotiline and 150 milligrams maprotiline, daily.

Detailed description

During treatment with maprotiline the patient should be kept under medical surveillance.

The recommended dose range is between 75 and 150 mg daily. Depending on the severity of the symptoms, patient response and tolerance, the daily dose may start at 25 mg (one to three times daily) or 75 mg (once daily) then gradually titrated up to the effective dose. Daily doses above 150 mg are not recommended.

The dosage schedule should be determined individually and adapted to the patient’s condition and response, e.g. by increasing the evening dose while lowering the doses given during the day or, alternatively, by administering only one daily dose. The aim is to achieve a therapeutic effect using the lowest possible doses, particularly in patients who are still growing or elderly patients with an unstable autonomic nervous system, since these patients are generally more likely to experience adverse events.

Elderly patients (more than 60 years of age)

In general, lower dosages are recommended. Initially, 10 mg 3 times daily or 25 mg once daily. If necessary, the daily dosage should be gradually increased in small increments up to 25 mg 3 times daily or 75 mg once daily, depending on tolerance and response.

Treatment discontinuation

Abrupt withdrawal or abrupt dose reduction should be avoided because of possible adverse reactions.

Dosage considerations

It should be swallowed whole with sufficient liquid.

Active ingredient


Maprotiline is a tetracyclic antidepressant, psychoanaleptics, non-selective mono-amine reuptake inhibitor, which shares a number of basic therapeutic properties with the tricyclic antidepressants. It displays a well-balanced spectrum of action, brightening mood and alleviating anxiety, agitation and psychomotor retardation. In masked depression, it can exert a favourable influence on somatic symptoms.

Read more about Maprotiline

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.